Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.
Br J Cancer
; 120(9): 896-902, 2019 04.
Article
in En
| MEDLINE
| ID: mdl-30944458
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoma, Hepatocellular
/
Sorafenib
/
Liver Neoplasms
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Br J Cancer
Year:
2019
Document type:
Article
Affiliation country:
France
Country of publication:
United kingdom